Clinical trials: Inflammatory Disorder
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Ulcerative Colitis
Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis
The purpose of this study is to determine the efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course for moderate flares of ulcerative colitis.
- Trial name
- CECUM (NCT02921555)
- Testing
- Methylprednisolone, Prednisone
- Where
- 29 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Inflammatory Bowel Disease (IBD)
Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g.
- Trial name
- NCT04345393
- Testing
- Digital Transformation Network (DTN) Program
- Where
- 4 sites in United States
- Volunteers
- 659 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Crohn's Disease
Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Despite extensive medical treatment, surgical resection is required in approximately 70% of the patients at some time. However, recurrence of the disease after operation occurs in the majority of patients and is a serious…
- Trial name
- NCT00609973
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of North Carolina, Chapel Hill
Crohn's Disease
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active Crohn's Disease (CD) that is refractory to conventional…
- Trial name
- Holiday (NCT02765256)
- Testing
- Fluconazole, Vancomycin, Neomycin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Lipopolysaccharide (LPS) Challenge in Depression
LPS Challenge in Individuals with Major Depressive Disorder
- Trial name
- NCT03142919
- Testing
- Lipopolysaccharide
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Hidradenitis Suppurativa (HS)
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.
- Trial name
- SHARPS (NCT02808975)
- Testing
- Adalimumab
- Where
- 55 sites in United States, Belgium and 21 more
- Volunteers
- 206 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylitis
Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)
The objective of this post-marketing observational study (PMOS) was to evaluate the effectiveness of adalimumab plus the AbbVie Care 2.0 patient support program in participants with rheumatoid arthritis (RA), ankylosing…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
- Trial name
- VALUE (NCT02750800)
- Testing
- Adalimumab, AbbVie Care 2.0
- Volunteers
- 427 people
- Sponsor
- AbbVie
Axial Spondyloarthritis
Individualizing Anti-Inflammatory Medications for Adults With Axial Spondyloarthritis: A Series of N-of 1 Trials
The purpose of this study is to compare selective cyclooxygenase-2 (COX-2) and non selective COX inhibitors with respect to the extent to which disease activity is improved without self reported, unacceptable side effects among…
- Trial name
- NCT04115098
- Testing
- Celecoxib, Naproxen, Meloxicam
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center, Houston
Colitis, Ulcerative
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
The primary objective of this trial is to understand the mechanism of action of BI655130 in patients with UC Secondary objectives are to explore clinical effect, safety and tolerability (including immunogenicity) of BI 655130…
- Trial name
- NCT03100864
- Testing
- Spesolimab
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- NCT04051944
- Testing
- Rozanolixizumab
- Where
- 14 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- UCB Biopharma SRL
Sars-CoV2
Rhu-pGSN for Severe Covid-19 Pneumonia
Study Objectives: Primary To assess the efficacy (survival without organ failure on Day 14) of three doses of rhu-pGSN administered intravenously (IV) plus standard of care (SOC) to hospitalized subjects with a primary diagnosis…
- Trial name
- NCT04358406
- Testing
- Recombinant human plasma gelsolin (Rhu-pGSN)
- Where
- 3 sites in Romania, Spain
- Volunteers
- 64 people
- Sponsor
- BioAegis Therapeutics Inc.
Crohn's Disease
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.
- Trial name
- NCT02015793
- Testing
- Adalimumab
- Volunteers
- 30 people
- Sponsor
- AbbVie
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis
The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT00385736
- Testing
- adalimumab
- Where
- 80 sites in United States, Austria and 11 more
- Volunteers
- 576 people
- Sponsor
- Abbott
Perianal Crohn's Disease
A Safety and Efficacy Study of BLI-1300 Ointment in Symptomatic Perianal Crohn's Disease
This randomized, placebo-controlled, parallel, multi-center, double-blind pilot study is designed to determine the effects of BLI-1300 ointment on perianal pain associated with active Perianal Crohn's Disease (PCD).
- Trial name
- NCT01442363
- Testing
- BLI-1300 low dose, BLI-1300 high dose
- Where
- 17 sites in United States
- Volunteers
- 4 people
- Sponsor
- Braintree Laboratories
Crohn's Disease
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.
- Trial name
- NCT03234907
- Testing
- Vedolizumab IV
- Where
- 29 sites in China
- Volunteers
- 215 people
- Sponsor
- Takeda
Colitis, Ulcerative
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
This is a Phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability, efficacy and dose-response of GSK2831781 in participants with moderate to severe active…
- Trial name
- NCT03893565
- Testing
- GSK2831781 - Double Blind Phase, GSK2831781 - Open Label phase
- Where
- 61 sites in United States, Bulgaria and 13 more
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Degenerative Joint Disease
R3 Delta Ceramic Acetabular System PAS U.S.
R3 Delta Post-Approval Study U.S.
- Trial name
- R3-PAS (NCT03056534)
- Testing
- R3 Biolox Delta Ceramic Acetabular System
- Where
- 8 sites in United States
- Volunteers
- 189 people
- Sponsor
- Smith & Nephew, Inc.
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.